Vitamin K2, MGP and skin elasticity are biologically connected—but direct facial-skin evidence is still missing. Here is what the research actually shows.
The short answer: vitamin K2 is relevant to skin biology because it can support the vitamin-K-dependent activation of Matrix Gla Protein (MGP), a local inhibitor of abnormal mineralisation. MGP has been identified in human dermal elastic fibres. But that does not yet prove that taking K2 improves facial skin elasticity, prevents wrinkles or reverses sagging: the key dermal evidence comes from a rare genetic calcification disorder, and direct oral K2 trials measuring normally ageing skin are lacking. K2 is therefore a credible part of structural biology—not a proven standalone skin-tightening treatment.
That distinction matters. Much of the online conversation presents vitamin K2 as a calcium traffic controller that sends calcium into bone and removes it from skin. The real biology is more precise, and the evidence is less complete. Here is what vitamin K2 does, why MGP is relevant to elastic fibres, and where the claims move beyond the data.
What is vitamin K2?
Vitamin K is a family of fat-soluble compounds. Vitamin K1, or phylloquinone, is found mainly in leafy green vegetables. Vitamin K2 refers to a group of menaquinones, including MK-4 and MK-7, found in varying amounts in fermented foods and some animal-derived foods.
Both K1 and K2 can act as cofactors for an enzyme that performs gamma-carboxylation. This chemical modification allows several vitamin-K-dependent proteins to function properly. Two of the most discussed are:
- Osteocalcin, a protein made by bone-forming cells and involved in bone mineralisation and turnover.
- Matrix Gla Protein (MGP), a locally produced protein involved in limiting inappropriate mineral deposition in soft tissues.
MK-7 is well absorbed and has a longer circulating half-life than vitamin K1 in comparative research. That makes it useful in supplementation studies, but it does not establish that MK-7 is clinically superior for skin.
Vitamin K does not physically carry calcium from skin to bone. It enables certain proteins to function; the result depends on the tissue, the person and the clinical context.
Why is MGP relevant to skin elasticity?
Elastic fibres give skin part of its capacity to stretch and recoil. Because elastin turns over very slowly, it accumulates damage over time. Ultraviolet exposure, enzymatic fragmentation, glycation, oxidation and mineralisation can all alter the elastic-fibre network. Calcification is one part of that wider ageing biology—not the sole explanation for loss of firmness.
The principal human dermal study behind the K2-and-skin hypothesis was published by Gheduzzi and colleagues in 2007. The researchers examined skin tissue and dermal fibroblasts from people with pseudoxanthoma elasticum (PXE), a rare inherited disorder characterised by abnormal calcification of elastic fibres. They found MGP within dermal elastic fibres and observed less carboxylated MGP in PXE tissue and fibroblasts than in controls.
This is important mechanistic evidence: it shows that MGP is present in the human dermal elastic-fibre environment and is associated with mineralisation biology. But it is not a supplementation trial. It did not give healthy adults MK-7, measure facial elasticity, count wrinkles or test whether K2 prevents ordinary age-related sagging.
Does vitamin K2 improve skin elasticity?
It has not yet been demonstrated in published human oral trials. The hypothesis is biologically plausible, but plausibility is not the same as a visible skin outcome.
| Question | What the evidence shows | What it does not prove |
|---|---|---|
| Can vitamin K support MGP carboxylation? | Yes. This is established vitamin-K-dependent biology, and supplementation reliably changes circulating markers of MGP carboxylation. | That changing a biomarker will improve facial skin elasticity or appearance. |
| Is MGP present in dermal elastic fibres? | Yes. Human tissue and fibroblast research has identified MGP in dermal elastic fibres, particularly in the context of PXE. | That low K2 is a common cause of normal skin ageing or facial sagging. |
| Does oral K2 improve wrinkles, firmness or elasticity? | No published human oral trial has directly established these cosmetic outcomes. | A skin-firming, wrinkle-reducing or lifting effect. |
| Does K2 support bone health? | Vitamin K contributes to normal bone biology. Supplement trials report mixed results, with some positive findings in specific postmenopausal or osteoporotic populations. | Preservation or rebuilding of the facial skeleton. |
| Does K2 affect vascular calcification or stiffness? | Some randomised trials show favourable signals, while reviews have found heterogeneous results. Clinical significance remains under study. | That an arterial outcome will occur in skin. |
What does the artery evidence add?
Arterial research strengthens the case that the vitamin K–MGP pathway is biologically active in humans, but it does not close the skin-evidence gap.
In a three-year randomised trial in healthy postmenopausal women, 180 micrograms of MK-7 per day reduced inactive MGP and improved selected measures of arterial stiffness, with the clearest signal in participants who had greater stiffness at baseline. More recently, a 2026 randomised trial in adults with symptomatic coronary artery disease found that 360 micrograms of MK-7 per day modestly attenuated the increase in coronary artery calcium over two years. The authors still called for larger studies with clinical outcomes.
These trials measured arteries—not skin—and neither tested wrinkles, facial firmness or dermal elastic-fibre calcification. They support the pathway, not a cosmetic claim.
Is there really a bone–skin axis?
There is a meaningful structural relationship, but it should not be described as calcium leaving facial bone and settling in facial skin. Facial ageing is multilayered: the dermal matrix, retaining ligaments, fat compartments, muscles and facial skeleton all change over time. Hormonal environment, ultraviolet exposure, smoking, nutrition and general health can influence more than one layer.
Vitamin-K-dependent proteins participate in bone and soft-tissue mineral biology, which makes K2 scientifically relevant to both territories. However, these are parallel tissue processes, not evidence of a direct calcium transfer from one to the other. No K2 study has shown preservation of the maxilla or mandible, restoration of lost facial volume or mechanical lifting of descended tissue. For the wider anatomy, read what causes facial volume loss as we age.
How much vitamin K2 should you take for skin?
There is no evidence-based K2 dose for skin elasticity. The 180-microgram dose often quoted online comes from MK-7 studies of arterial stiffness, bone markers or other non-skin outcomes; it should not be converted into a facial-skin recommendation.
European guidance sets an adequate intake of 70 micrograms per day for vitamin K in adults, based on phylloquinone, not a separate requirement for K2 or a therapeutic skin dose. Needs and supplement decisions can differ with diet, health status and medication use.
Food sources of vitamin K
- Vitamin K1: kale, spinach, broccoli and other green vegetables.
- Vitamin K2 as MK-7: natto is the most concentrated well-characterised food source.
- Other menaquinones: hard and fermented cheeses contain variable forms and amounts; egg yolks, meat and some dairy foods can provide smaller, variable quantities.
Food-composition data for menaquinones are less complete than for K1, so claims that an entire population is “low in K2” should be treated cautiously.
Do vitamin D3 and K2 need to be taken together?
They can be taken together, but the popular phrase that D3 absorbs calcium while K2 “puts it in the right place” is too absolute. Vitamin D supports intestinal calcium absorption; vitamin K supports the carboxylation of proteins including osteocalcin and MGP. Their functions are complementary, but combination studies do not prove that everyone taking vitamin D needs K2, nor that the pair prevents calcium from reaching skin.
Safety note: vitamin K can interact seriously with warfarin and other vitamin K antagonists. Anyone taking these medicines should not start, stop or substantially change vitamin K intake without guidance from the clinician managing their anticoagulation. Seek individual advice if you have a condition affecting fat absorption or take regular medication.
THE STRUCTURAL RESPONSE
AGELESS
Structure · Matrix · Cellular Energy
Skin laxity cannot be reduced to one nutrient or one protein. AGELESS places vitamin K2 within a broader formulation architecture spanning connective-tissue cofactors, dermal-matrix biology, cellular energy and antioxidant support. The role of K2 here is formulation rationale—not a claim that it rebuilds facial bone, removes calcium from skin or mechanically lifts the face.
Explore AGELESS The structural protocol by SKINĒDIT →Frequently asked questions
Does vitamin K2 help skin elasticity?
Vitamin K2 supports the activation of MGP, a protein involved in limiting abnormal mineralisation, and MGP is present in dermal elastic fibres. However, no published human oral trial has shown that K2 supplementation improves facial skin elasticity. The mechanism is credible; the cosmetic outcome is unproven.
Is vitamin K2 good for wrinkles or sagging skin?
There is not enough direct evidence to recommend K2 as a wrinkle or sagging-skin treatment. Wrinkles and laxity arise from multiple changes involving collagen, elastin, ultraviolet damage, ligaments, fat compartments, muscle and bone. K2 cannot be assumed to correct them from its MGP mechanism alone.
Can vitamin K2 reverse elastocalcinosis?
No human trial has shown that oral K2 reverses established mineralisation of dermal elastic fibres. Research in PXE helps explain the role of carboxylated MGP in calcification biology, but it does not demonstrate reversal in normally ageing skin.
What is the difference between vitamin K1 and K2?
Vitamin K1 is phylloquinone, found mainly in green vegetables. Vitamin K2 is a family of menaquinones, including MK-4 and MK-7. Both can support vitamin-K-dependent carboxylation; it is misleading to say K1 is only for clotting while K2 alone works in bone and soft tissue. MK-7 has a longer circulating half-life, but no form has proven superior for skin elasticity.
How much vitamin K2 should I take?
There is no established K2 dose for skin. Doses such as 180 micrograms per day come from trials investigating non-skin outcomes and are not universal recommendations. Food intake, health status and medication use should guide an individual decision with a qualified clinician.
Can you take vitamin K2 and D3 together?
They can be combined, and both are involved in mineral biology, but taking them together has not been shown to improve skin elasticity. If you use warfarin or another vitamin K antagonist, do not change your vitamin K intake without medical guidance.
Related reading
- The calcium paradox: why skin stiffens with age
- Best supplements for skin firmness and elasticity
- What causes facial volume loss as we age?
References
- Gheduzzi D, Boraldi F, Annovi G, et al. Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Laboratory Investigation. 2007;87:998–1008. doi:10.1038/labinvest.3700667.
- Heinz A. Elastic fibers during aging and disease. Ageing Research Reviews. 2021;66:101255. PMID: 33434682.
- Knapen MHJ, Braam LAJLM, Drummen NE, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015;113(5):1135–1144. doi:10.1160/TH14-08-0675.
- Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology. 2026;11(8):719–726. doi:10.1001/jamacardio.2026.1279.
- Zhou M, Li Y, Qi S, et al. Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review. Journal of Bone and Mineral Metabolism. 2022;40(5):763–772. PMID: 35711002.
- European Food Safety Authority. Dietary reference values for vitamin K. EFSA Journal. 2017;15(5):4780. EFSA opinion.
- NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals. NIH ODS.
Evidence note: this article distinguishes biochemical mechanism, human tissue evidence, non-skin clinical trials and direct cosmetic outcomes. Evidence from MGP biomarkers, bone or arteries is not treated as proof of a facial-skin benefit. Last evidence review: August 2026.
Jaouad Bentaguena is the founder of SKINĒDIT Paris. He researches and writes the SKINĒDIT's Intelligence journal himself — working from the peer-reviewed literature and alongside the scientists and clinical partners behind each protocol, to translate the science of deep skincare into something clear enough to act on.
About the author
